Company Update (NASDAQ:ZGNX): New Data on Zogenix, Inc.’s ZX008 for Dravet Syndrome to be Presented at 69th Annual American Epilepsy Society Meeting

Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the presentation of clinical and scientific posters, and the hosting of a scientific exhibit room at the 69th Annual American Epilepsy Society Meeting, which will take place in Philadelphia, PA, from December 4 – 8, 2015.

One poster will report efficacy data from a new cohort of 7 patients treated with ZX008 (low-dose fenfluramine) for Dravet syndrome. A second poster will focus on the evaluation of cardiovascular safety related to the treatment of the same 7 patients. A third poster reports on investigations into the mechanism of action for fenfluramine as a treatment for Dravet syndrome using a gene knockout zebrafish model.

In addition, on Monday, December 7, 2015, from 8:00 AM – 11:00 AM, Zogenix will host the “History of the Use of Low-dose Fenfluramine in Pediatric Epilepsy: An Intriguing Past, Present, and Future” in a Scientific Exhibit room highlighting all of the posters and publications focused on low-dose fenfluramine as a potential treatment for Dravet syndrome generated to date.

Zogenix expects to initiate Phase 3 clinical studies for ZX008 in 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome. (Original Source)

Shares of Zogenix closed yesterday at $14.21, down $0.38 or -2.60%. ZGNX has a 1-year high of $21.65 and a 1-year low of $8.64. The stock’s 50-day moving average is $12.72 and its 200-day moving average is $15.11.

On the ratings front, Zogenix has been the subject of a number of recent research reports. In a report issued on November 11, Brean Murray Carret analyst Difei Yang maintained a Buy rating on ZGNX, with a price target of $28, which implies an upside of 97.0% from current levels. Separately, on November 10, William Blair’s Tim Lugo reiterated a Hold rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Difei Yang and Tim Lugo have a total average return of 2.4% and -7.3% respectively. Yang has a success rate of 47.0% and is ranked #1151 out of 3641 analysts, while Lugo has a success rate of 32.1% and is ranked #3393.

The street is mostly Bullish on ZGNX stock. Out of 4 analysts who cover the stock, 3 suggest a Buy rating and one recommends to Hold the stock. The 12-month average price target assigned to the stock is $23.00, which represents a potential upside of 61.9% from where the stock is currently trading.

Zogenix Inc is a pharmaceutical company engaged in commercializing & developing therapies that address clinical needs for people living with pain-related and CNS disorders that needs treatment alternatives to help return to normal daily functioning.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts